chlorzoxazone has been researched along with Liver Dysfunction in 4 studies
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mephenytoin metabolism was significantly decreased in both patients with mild liver disease (Child-Pugh score of 5/6) (-63% [95% confidence interval (CI), -86% to -40%]; P = ." | 2.72 | Liver disease selectively modulates cytochrome P450--mediated metabolism. ( Branch, RA; Chaves-Gnecco, D; Frye, RF; Matzke, GR; Rabinovitz, M; Shaikh, OS; Zgheib, NK, 2006) |
| "Isoniazid is a widely used drug for the treatment of tuberculosis, but hepatotoxicity is a major concern during treatment." | 1.35 | Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. ( Chen, J; Dong, G; He, C; Liu, Y; Peng, R; Yue, J, 2009) |
| "001) and other pharmacokinetic parameters." | 1.30 | Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. ( Basu, P; Kessova, I; Lieber, CS; Mishin, VM; Oneta, CM; Rosman, AS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yue, J | 1 |
| Dong, G | 1 |
| He, C | 1 |
| Chen, J | 1 |
| Liu, Y | 1 |
| Peng, R | 1 |
| Frye, RF | 1 |
| Zgheib, NK | 1 |
| Matzke, GR | 1 |
| Chaves-Gnecco, D | 1 |
| Rabinovitz, M | 1 |
| Shaikh, OS | 1 |
| Branch, RA | 1 |
| Tanaka, E | 1 |
| Breimer, DD | 1 |
| Mishin, VM | 1 |
| Rosman, AS | 1 |
| Basu, P | 1 |
| Kessova, I | 1 |
| Oneta, CM | 1 |
| Lieber, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone When Administered Individually or Concurrently[NCT05257447] | Phase 1 | 19 participants (Actual) | Interventional | 2022-04-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for chlorzoxazone and Liver Dysfunction
| Article | Year |
|---|---|
In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease.
Topics: Aminopyrine; Antipyrine; Breath Tests; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome | 1997 |
1 trial available for chlorzoxazone and Liver Dysfunction
| Article | Year |
|---|---|
Liver disease selectively modulates cytochrome P450--mediated metabolism.
Topics: Administration, Oral; Adult; Anticonvulsants; Antihypertensive Agents; Caffeine; Case-Control Studie | 2006 |
2 other studies available for chlorzoxazone and Liver Dysfunction
| Article | Year |
|---|---|
Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Alanine Transaminase; Aniline Compounds; Animals; Aspartate Aminotransf | 2009 |
Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans.
Topics: Alcoholism; Biomarkers; Chlorzoxazone; Cytochrome P-450 Enzyme System; Enzyme Induction; Humans; Liv | 1998 |